Xtandi vs Zytiga: How do they compare?
Xtandi (enzalutamide) and Zytiga (abiraterone acetate) are both drugs that are used in the treatment of prostate cancer. Results from various analyses indicate that Xtandi is more effective than Zytiga in patients with castration-resistant prostate cancer that has spread or metastasized, although it’s more commonly associated with fatigue.
Xtandi (enzalutamide) | Zytiga (abiraterone acetate) | |
Company | Astella Pharma | Janssen Biotech |
Approval date | First approved in the US in 2012 | First approved in the US in 2011 |
Indication/usage | For the treatment of: | For the treatment of: |
Dosage form | Capsules (40mg) and tablets (80mg, 40mg) | Tablets (uncoated 250mg, film-coated 500mg) |
Generic available | Generic capsules only available | Generics available |
Administration | Orally | Orally |
Dosing schedule | Capsules and tablets should be swallowed whole. | Tablets must be swallowed whole and taken on an empty stomach. |
Drug type | Small molecule | Small molecule |
Mechanism of action | Androgen receptor inhibitor | CYP17 inhibitor |
Side effects / adverse effects | The most common adverse reactions (≥ 10%) are: Results from a systematic review and meta-analysis showed that Xtandi was associated with a significantly elevated risk of side effects (730 patients, odds ratio 0.35, 95% CI 0.13-0.92, p=0.03), especially fatigue (2477 patients, odds ratio 0.46, 95% CI 0.34-0.63, p<0.00001), compared with Zytiga in patients with metastatic castration-resistant prostate cancer. However, a separate systematic review and meta-analysis comparing Xtandi with Zytiga in patients with metastatic castration-resistant prostate cancer did not find a significant difference between the two groups in terms of overall adverse events (730 patients, relative risk 0.42, 95% CI 0.14-1.31, p=0.14), but Xtandi was associated with a higher risk of fatigue (2555 patients, relative risk 0.45, 95% CI 0.24-0.85, p=0.01). | The most common adverse reactions (≥ 10%) are: |
Efficacy | Results from three systematic reviews and meta-analyses show that Xtandi is more effective than Ztygia for treating metastatic castration-resistant prostate cancer. In two reviews prostate-specific antigen responses were higher for people receiving Xtandi than Zytiga (790 patients, odds ratio 0.47, 95% CI 0.29-0.77, p=0.003 and 867 patients, risk ratio 0.69, 95% CI 0.61-0.79, p<0.00001). In a third review, Xtandi was more effective than Zytiga at improving radiographic progression-free survival (hazard ratio=0.516, 95% CI 0.438-0.608) and time to prostate-specific antigen progression (hazard ratio 0.365, 95% CI 0.303-0.441), but not overall survival (p=0.21), although more work was noted to be needed to confirm these findings.Other studies have found Xtandi to be associated with an overall survival benefit compared with Zytiga in patients with metastatic castration-resistant prostate cancer, especially in older patients with more comorbidities who are not candidates for docetaxel (median overall survival 18.9 months vs 13.6 months, respectively (p<0.001). | |
Drug interactions | | |
Warnings and precautions | | |
Special patient populations | Do not use in patients with existing severe hepatic impairment (Child-Pugh Class) |
Related medical questions
- Why has it stopped working and what do I take next?
- How long does it work for?
- Xtandi vs Zytiga: How do they compare?
- Does it lower prostate-specific antigen (PSA)?
- Is this a chemotherapy drug and how does it work?
- What is it used for?
- Why has it stopped working and what do I take next?
- How long does it work for?
- Xtandi vs Zytiga: How do they compare?
- Does it lower prostate-specific antigen (PSA)?
- Is this a chemotherapy drug and how does it work?
- What is it used for?
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions